glp-1 and eating disorder weight-loss drugs may also reduce binge Role of GLP-1A Receptor Agonists

Though most weight loss patches are marketed as GLP-1 patches, they do not contain a GLP-1 agonist, such as semaglutide or tirzepatide

Despite the promise of GLP-1 agonists in treating both diabetes and obesity, there are several practical considerations that patients and healthcare providers should take into account when considering these drugs for off-label use: Understand the Off-Label Nature of the Treatment: Patients who are prescribed GLP-1 agonists for weight loss should be made aware that this use is off-label, meaning that the FDA has not officially approved the drug for this purpose

If you're ever genuinely unsure, call your clinic

Divide the target dose by the concentration: 0.25 mg 2.5 mg/mL = 0.10 mL Step 3 convert to insulin-syringe units

Neuropharmacology (2018) 136(Pt B):2806